{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:57:15Z","timestamp":1790902635350,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00280-009-1099-1","type":"journal-article","created":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T01:47:54Z","timestamp":1250214474000},"page":"923-930","source":"Crossref","is-referenced-by-count":42,"title":["Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane"],"prefix":"10.1007","volume":"65","author":[{"given":"Zhongling","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,15]]},"reference":[{"key":"1099_CR1","first-page":"573","volume":"8","author":"E Auzenne","year":"2002","unstructured":"Auzenne E, Donato NJ, Li C, Leroux E, Price RE, Farquhar D, Klostergaard J (2002) Superior therapeutic profile of poly-l-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin Cancer Res 8:573","journal-title":"Clin Cancer Res"},{"key":"1099_CR2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1023\/A:1010931127745","volume":"18","author":"P Calvo","year":"2001","unstructured":"Calvo P, Gouritin B, Chacun H, Desmaele D, D\u2019Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P (2001) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18:1157","journal-title":"Pharm Res"},{"key":"1099_CR3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317","journal-title":"Clin Cancer Res"},{"key":"1099_CR4","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590","journal-title":"Eur J Cancer"},{"key":"1099_CR5","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794","journal-title":"J Clin Oncol"},{"key":"1099_CR6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jpba.2005.02.023","volume":"39","author":"SC Kim","year":"2005","unstructured":"Kim SC, Yu J, Lee JW, Park ES, Chi SC (2005) Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution. J Pharm Biomed Anal 39:170","journal-title":"J Pharm Biomed Anal"},{"key":"1099_CR7","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/13543784.13.11.1501","volume":"13","author":"CJ Langer","year":"2004","unstructured":"Langer CJ (2004) CT-2103: emerging utility and therapy for solid tumours. Expert Opin Investig Drugs 13:1501","journal-title":"Expert Opin Investig Drugs"},{"key":"1099_CR8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/JTO.0b013e3181753b4b","volume":"3","author":"CJ Langer","year":"2008","unstructured":"Langer CJ, O\u2019Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:623","journal-title":"J Thorac Oncol"},{"key":"1099_CR9","first-page":"2829","volume":"6","author":"C Li","year":"2000","unstructured":"Li C, Ke S, Wu QP, Tansey W, Hunter N, Buchmiller LM, Milas L, Charnsangavej C, Wallace S (2000) Tumor irradiation enhances the tumor-specific distribution of poly(l-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6:2829","journal-title":"Clin Cancer Res"},{"key":"1099_CR10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s002800000168","volume":"46","author":"C Li","year":"2000","unstructured":"Li C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S (2000) Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 46:416","journal-title":"Cancer Chemother Pharmacol"},{"key":"1099_CR11","first-page":"891","volume":"5","author":"C Li","year":"1999","unstructured":"Li C, Price JE, Milas L, Hunter NR, Ke S, Yu DF, Charnsangavej C, Wallace S (1999) Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 5:891","journal-title":"Clin Cancer Res"},{"key":"1099_CR12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00001813-199608000-00004","volume":"7","author":"C Li","year":"1996","unstructured":"Li C, Yu D, Inoue T, Yang DJ, Milas L, Hunter NR, Kim EE, Wallace S (1996) Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug. Anticancer Drugs 7:642","journal-title":"Anticancer Drugs"},{"key":"1099_CR13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-007-9034-y","volume":"25","author":"NU Lin","year":"2007","unstructured":"Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN (2007) Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 25:369","journal-title":"Invest New Drugs"},{"key":"1099_CR14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejca.2003.09.022","volume":"40","author":"X Lin","year":"2004","unstructured":"Lin X, Zhang Q, Rice JR, Stewart DR, Nowotnik DP, Howell SB (2004) Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer 40:291","journal-title":"Eur J Cancer"},{"key":"1099_CR15","first-page":"53","volume":"71","author":"SM Longnecker","year":"1987","unstructured":"Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M (1987) High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53","journal-title":"Cancer Treat Rep"},{"key":"1099_CR16","first-page":"4269","volume":"17","author":"AS Multani","year":"1997","unstructured":"Multani AS, Li C, Ozen M, Yadav M, Yu DF, Wallace S, Pathak S (1997) Paclitaxel and water-soluble poly (l-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line. Anticancer Res 17:4269","journal-title":"Anticancer Res"},{"key":"1099_CR17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/JTO.0b013e31817c6b68","volume":"3","author":"ME O\u2019Brien","year":"2008","unstructured":"O\u2019Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW (2008) Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:728","journal-title":"J Thorac Oncol"},{"key":"1099_CR18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<600::AID-IJC18>3.0.CO;2-C","volume":"75","author":"V Omelyanenko","year":"1998","unstructured":"Omelyanenko V, Gentry C, Kopeckova P, Kopecek J (1998) HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer 75:600","journal-title":"Int J Cancer"},{"key":"1099_CR19","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/sj.bjc.6604372","volume":"98","author":"L Paz-Ares","year":"2008","unstructured":"Paz-Ares L, Ross H, O\u2019Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, Garcia-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P (2008) Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 98:1608","journal-title":"Br J Cancer"},{"key":"1099_CR20","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-05-2169","volume":"12","author":"JR Rice","year":"2006","unstructured":"Rice JR, Gerberich JL, Nowotnik DP, Howell SB (2006) Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 12:2248","journal-title":"Clin Cancer Res"},{"key":"1099_CR21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3816\/CLC.2005.n.039","volume":"7","author":"DA Richards","year":"2005","unstructured":"Richards DA, Richards P, Bodkin D, Neubauer MA, Oldham F (2005) Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study. Clin Lung Cancer 7:215","journal-title":"Clin Lung Cancer"},{"key":"1099_CR22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004","journal-title":"N Engl J Med"},{"key":"1099_CR23","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/JCO.2004.12.043","volume":"22","author":"P Sabbatini","year":"2004","unstructured":"Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D (2004) Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol 22:4523","journal-title":"J Clin Oncol"},{"key":"1099_CR24","first-page":"5877","volume":"53","author":"A Sharma","year":"1993","unstructured":"Sharma A, Mayhew E, Straubinger RM (1993) Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res 53:5877","journal-title":"Cancer Res"},{"key":"1099_CR25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/0-306-47932-X_6","volume":"519","author":"JW Singer","year":"2003","unstructured":"Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, Bolton M, Garzone P (2003) Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv Exp Med Biol 519:81","journal-title":"Adv Exp Med Biol"},{"key":"1099_CR26","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","volume":"11","author":"A Sparreboom","year":"2005","unstructured":"Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11:4136","journal-title":"Clin Cancer Res"},{"key":"1099_CR27","doi-asserted-by":"crossref","unstructured":"Wang X, Zhao G, Van S, Jiang N, Yu L, Vera D, Howell SB (2009) Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu\/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol [Epub ahead of print]","DOI":"10.1007\/s00280-009-1058-x"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1099-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:32:28Z","timestamp":1558485148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1099-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,15]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1099-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,15]]}}}